c-Met: A Promising Therapeutic Target in Bladder Cancer

被引：13

作者：

Feng, Yanfei ^{[1
]}

Yang, Zitong ^{[2
]}

Xu, Xin ^{[2
,3
]}

机构：

[1] Zhejiang Chinese Med Univ, Affiliated Coll 2, Hangzhou, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Hangzhou, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, 79th Qingchun Rd, Hangzhou 310003, Peoples R China

来源：

CANCER MANAGEMENT AND RESEARCH | 2022年 / 14卷

基金：

中国国家自然科学基金;

关键词：

c; -Met; HGF; noncoding RNA; bladder cancer; review; HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; URINARY-BLADDER; SCATTER FACTOR; PROGNOSTIC INDICATOR; LUNG ADENOCARCINOMA; EXPRESSION; MIGRATION;

D O I：

10.2147/CMAR.S369175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal-epithelial transition factor (c-Met) belongs to the tyrosine kinase receptor family and is overexpressed in various human cancers. Its ligand is hepatocyte growth factor (HGF), and the HGF/c-Met signaling pathway is involved in a wide range of cellular processes, including cell proliferation, migration, and metastasis. Emerging studies have indicated that c-Met expression is strongly associated with bladder cancer (BCa) development and prognosis. Therefore, c-Met is a potential therapeutic target for BCa treatment. Recently, the aberrant expression of noncoding RNAs was found to play a significant role in tumour progression. There is a close connection between c-Met and noncoding RNA. Herein, we summarized the biological function and prognostic value of c-Met in BCa, as well as its potential role as a drug target. The relation of c-Met and ncRNA was also described in the paper.

引用

页码：2379 / 2388

页数：10

共 50 条

[41] Increased miR-323a induces bladder cancer cell apoptosis by suppressing c-Met
Qiu, Jun
Zeng, Fu-Ren
Fang, Yi
Li, Jian
Xiao, Sheng-Ying
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2019, 35 (09) : 542 - 549
[42] HGF/c-Met: A Key Promoter in Liver Regeneration
Zhao, Yang
Ye, Wenling
Wang, Yan-Dong
Chen, Wei-Dong
FRONTIERS IN PHARMACOLOGY, 2022, 13
[43] Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
Breen, Laura
Gaule, Patricia B.
Canonici, Alexandra
Walsh, Naomi
Collins, Denis M.
Cremona, Mattia
Hennessy, Bryan T.
Duffy, Michael J.
Crown, John
O' Donovan, Norma
Eustace, Alex J.
INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1365 - 1372
[44] The role of HGF/c-MET signaling pathway in lymphoma
Bao Quoc Lam
Dai, Lu
Qin, Zhiqiang
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 : 1 - 8
[45] c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression
Sim, Wen Jing
Iyengar, Prasanna Vasudevan
Lama, Dilraj
Lui, Sarah Kit Leng
Ng, Hsien Chun
Haviv-Shapira, Lior
Domany, Eytan
Kappei, Dennis
Tan, Tuan Zea
Saie, Azad
Jaynes, Patrick William
Verma, Chandra Shekhar
Kumar, Alan Prem
Rouanne, Mathieu
Ha, Hong Koo
Radulescu, Camelia
ten Dijke, Peter
Eichhorn, Pieter Johan Adam
Thiery, Jean Paul
NATURE COMMUNICATIONS, 2019, 10 (1)
[46] Identifying Mechanisms for Therapeutic Intervention in Chordoma c-Met Oncoprotein
Ostroumov, Elena
Hunter, Christopher J.
SPINE, 2008, 33 (25) : 2774 - 2780
[47] SRPKs: a promising therapeutic target in cancer
Tufail, Muhammad
Wu, Changxin
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3093 - 3112
[48] Biological significance and targeting of c-Met tyrosine kinase receptor in cancer
Goetsch, Liliane
Caussanel, Veronique
Corvaia, Nathalie
FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 454 - 473
[49] A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
Sun, Zu-Jun
Wu, Yi
Hou, Wei-Hua
Wang, Yu-Xiong
Yuan, Qing-Yun
Wang, Hui-Jie
Yu, Min
ONCOTARGET, 2017, 8 (17) : 29067 - 29079
[50] miRNAs: A Promising Target in the Chemoresistance of Bladder Cancer
Cai, Zhonglin
Zhang, Fa
Chen, Weijie
Zhang, Jianzhong
Li, Hongjun
ONCOTARGETS AND THERAPY, 2019, 12 : 1805 - 1816

← 1 2 3 4 5 →